1056562-54-9 Usage
Molecular structure
2-(3-morpholin-4-ylmethyl-imidazo[2,1-b]thiazol-6-yl)-phenylamine consists of a phenylamine molecule connected to a morpholine ring and an imidazo[2,1-b]thiazol-6-yl group.
Complex chemical compound
The compound has a long and specific chemical name, indicating a complex structure.
Potential applications
It may have potential applications in medicinal or pharmaceutical research due to its unique structure.
Similar compounds' pharmacological properties
Compounds with similar structures have been investigated for their potential pharmacological properties.
Need for further research
More research and analysis are needed to fully understand the potential uses and properties of this specific compound.
Check Digit Verification of cas no
The CAS Registry Mumber 1056562-54-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,5,6,5,6 and 2 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1056562-54:
(9*1)+(8*0)+(7*5)+(6*6)+(5*5)+(4*6)+(3*2)+(2*5)+(1*4)=149
149 % 10 = 9
So 1056562-54-9 is a valid CAS Registry Number.
1056562-54-9Relevant articles and documents
The identification of the SIRT1 activator SRT2104 as a clinical candidate
Ng, Pui Yee,Bemis, Jean E.,Disch, Jeremy S.,Vu, Chi B.,Oalmann, Christopher J.,Lynch, Amy V.,Carney, David P.,Riera, Thomas V.,Song, Jeffrey,Smith, Jesse J.,Lavu, Siva,Tornblom, Angela,Duncan, Meghan,Yeager, Marie,Kriksciukaite, Kristina,Gupta, Akanksha,Suri, Vipin,Elliot, Peter J.,Milne, Jill C.,Nunes, Joseph J.,Jirousek, Michael R.,Vlasuk, George P.,Ellis, James L.,Perni, Robert B.
, p. 793 - 797 (2013/12/04)
We have identified SRT2104 (4) as the first direct synthetic SIRT1 activator clinical candidate. The compound was derived from the optimization of a previously described imidazo[1,2-b]thiazole scaffold. SRT2104 was selected as a development candidate based on a combination of biochemical activity and pharmacokinetic profile. The in vivo characteristics of SRT2104 were superior to those of analogues with similar activation profiles. The overall preclinical profile suggests that the compound has potential to provide therapeutic benefit in a clinical setting. 2013 Bentham Science Publishers.
